[Safety and efficacy of the use of eltrombopag in a case of severe acquired bone marrow aplasia]
- PMID: 29798814
- DOI: 10.1016/j.anpedi.2018.04.011
[Safety and efficacy of the use of eltrombopag in a case of severe acquired bone marrow aplasia]
Similar articles
-
Eltrombopag: a review of its use in patients with severe aplastic anaemia.Drugs. 2015 Apr;75(5):525-31. doi: 10.1007/s40265-015-0363-4. Drugs. 2015. PMID: 25700916 Review.
-
Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia.N Engl J Med. 2017 Apr 20;376(16):1540-1550. doi: 10.1056/NEJMoa1613878. N Engl J Med. 2017. PMID: 28423296 Free PMC article. Clinical Trial.
-
Longitudinal evaluation of eltrombopag in paediatric acquired severe aplastic anaemia.Br J Haematol. 2020 Aug;190(3):e157-e159. doi: 10.1111/bjh.16766. Epub 2020 Jun 12. Br J Haematol. 2020. PMID: 32529633 Clinical Trial. No abstract available.
-
Efficacy, Safety, and Population Pharmacokinetics of Eltrombopag in Children with Different Severities of Aplastic Anemia.J Clin Pharmacol. 2024 Aug;64(8):932-943. doi: 10.1002/jcph.2430. Epub 2024 Mar 18. J Clin Pharmacol. 2024. PMID: 38497347
-
Eltrombopag--an oral thrombopoietin agonist.Eur Rev Med Pharmacol Sci. 2012 Jun;16(6):743-6. Eur Rev Med Pharmacol Sci. 2012. PMID: 22913204 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical